AbbVie's Etentamig Clears Phase 3 Bar in Relapsed Myeloma

AbbVie said Thursday that its bispecific T-cell engager etentamig improved response rates and progression-free survival in a phase 3 trial in patients with relapsed or refractory multiple myeloma; ABBV shares last closed at 256.46, down 1.44% on the day.

AbbVie (ABBV) said Thursday that etentamig, its bispecific T-cell engager for multiple myeloma, improved both response rates and progression-free survival in a phase 3 study of patients whose disease had returned or stopped responding to prior therapy. The readout moves the drug out of the mid-stage pack and into the small group of assets with registrational data in one of oncology's most competitive settings.

The company did not attach headline efficacy numbers to the disclosure reported by Fierce Biotech beyond the direction of the two endpoints. That leaves the magnitude of benefit — and therefore the drug's commercial ceiling — an open question until the full dataset is presented at a medical meeting or filed with regulators.

What a bispecific T-cell engager actually does

A bispecific T-cell engager is an antibody built with two binding arms. One arm latches onto a protein on the surface of the cancer cell; the other grabs a receptor on a T cell, the immune system's killing cell. The molecule physically pulls the two together, forcing an immune attack that the T cell would not otherwise mount. It is an off-the-shelf approach: unlike CAR-T therapy, no cells have to be harvested from the patient, engineered and shipped back, which is why bispecifics have spread quickly through myeloma treatment centers that cannot support cell-therapy logistics.

The trade-off is toxicity management. The same forced immune activation that kills tumor cells can produce cytokine release syndrome and neurological side effects, which is why these drugs are typically started with step-up dosing under monitoring. Any commercial assessment of etentamig will hinge as much on its safety and administration profile as on its response rate.

Relapsed and refractory myeloma is the hardest place to compete

Multiple myeloma is a cancer of plasma cells in the bone marrow. It is treatable but, in almost all cases, recurring: patients cycle through proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibodies, and each relapse leaves fewer options and a shorter remission. Patients described as relapsed/refractory — the population in AbbVie's trial — have already exhausted several of those lines.

That is precisely where the current wave of bispecifics has established itself, with molecules aimed at two tumor targets: BCMA, a protein expressed almost exclusively on plasma cells, and GPRC5D, a second surface target that offers an alternative when BCMA-directed therapy fails. Approved agents in both categories are already on the market, and cell therapies occupy the same late-line real estate. Etentamig therefore arrives into a field where physicians have choices, and where differentiation comes from sequencing, tolerability and convenience rather than from being first.

Progression-free survival — the length of time a patient lives without the cancer worsening — is the endpoint that matters most to prescribers here, because response rates in heavily pretreated myeloma have become uniformly high across the class. AbbVie reported improvement on both. The size of the progression-free survival gain, the comparator arm used, and the duration of follow-up are the three details that will determine whether this drug is viewed as a class entrant or a class leader.

The share reaction and the size problem

Trial news of this kind rarely moves a company of AbbVie's scale on its own. The stock last closed at 256.46, down 1.44% on the day, according to market data as of 20:00 GMT on Sept. 4, 2026, with a session range of 255.58 to 258.91 against a prior close of 260.21. That was a weaker session than the broad market: the S&P 500 tracker SPY finished at $770.19, off 0.39%, a gap of roughly 1.05 percentage points on the day. The Dow tracker DIA fell 0.53% to $534.08, while the Nasdaq 100 tracker QQQ closed higher at $718.96, up 0.18%.

The read-across is straightforward. For a diversified large-cap pharmaceutical company, a single positive phase 3 in a crowded indication is a pipeline validation rather than a revaluation event. It matters more for what it says about the platform — that AbbVie can execute in T-cell engagers, a modality it will want to deploy across other tumor types — than for what etentamig alone might sell.

What has to happen next

Three things will define whether Thursday's disclosure becomes a commercial story:

• The full dataset. Response rate and progression-free survival numbers, the control arm, and the adverse-event profile including rates of cytokine release syndrome. Until those land, the announcement is directional only.
• Regulatory filings. Whether AbbVie takes the data to the FDA and EU regulators, and on what timeline, signals how confident the company is in the strength of the result.
• Positioning against incumbents. Late-line myeloma is increasingly about sequencing: which target you use first, and what remains available after it fails. A drug that works after prior BCMA exposure is worth considerably more than one that does not.

There is also a broader industry point. Bispecific T-cell engagers were, for years, a modality with one commercial success and a long list of failures. Myeloma changed that, and the number of programs now competing in the same relapsed population reflects how quickly capital followed the science. The consequence is that clinical success no longer guarantees commercial success — the bar has shifted from demonstrating that a mechanism works to demonstrating that it works better, or more safely, or in patients other drugs have already failed.

For AbbVie, which has spent years building oncology and immunology franchises to offset the erosion of its legacy blockbuster, etentamig is one of several assets that need to clear that second bar, not just the first. Thursday's data says the science is real. The economics remain to be shown.

Key facts

• Ticker and last close: ABBV — 256.46, -1.44%, as of 20:00 GMT Sept. 4, 2026
• Drug: Etentamig, a bispecific T-cell engager
• Trial result: Improved response rates and progression-free survival in phase 3
• Patient population: Relapsed or refractory multiple myeloma

Frequently asked questions

What did AbbVie report about etentamig?

AbbVie said on Thursday that phase 3 data for etentamig, a bispecific T-cell engager, showed improvements in both response rates and progression-free survival among patients with relapsed or refractory multiple myeloma. The company did not attach specific efficacy figures to that disclosure, so the magnitude of the benefit is not yet public.

How does a bispecific T-cell engager work?

It is an antibody with two binding arms. One attaches to a protein on the surface of a cancer cell and the other grabs a receptor on a T cell, physically forcing the immune cell into contact with the tumor cell so it can kill it. Unlike CAR-T therapy, it is an off-the-shelf product requiring no cell harvesting.

What does relapsed/refractory multiple myeloma mean?

Multiple myeloma is a cancer of plasma cells in the bone marrow. Relapsed means the disease has returned after treatment; refractory means it no longer responds to a given therapy. Patients in this category have typically already cycled through several classes of drugs, leaving fewer remaining options and shorter periods of remission.

How did AbbVie shares perform?

ABBV last closed at 256.46, down 1.44% on the day, with a session range of 255.58 to 258.91 against a prior close of 260.21, as of 20:00 GMT on Sept. 4, 2026. That trailed the S&P 500 tracker SPY, which closed at $770.19, down 0.39%, and the Dow tracker DIA, off 0.53%.

Why is progression-free survival the key endpoint?

In heavily pretreated myeloma, response rates across the bispecific class have converged at high levels, so they no longer separate drugs from one another. Progression-free survival — how long a patient lives before the cancer worsens — is the measure prescribers and payers use to judge whether a new agent offers real additional benefit.

What competition does etentamig face?

Late-line myeloma already has approved bispecific antibodies directed at BCMA and at GPRC5D, two proteins found on plasma cells, plus CAR-T cell therapies serving similar patients. Differentiation now depends on tolerability, administration convenience and whether a drug still works in patients who have already failed a BCMA-targeting therapy.

Sources

• AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial — Fierce Biotech

Photo: https://kaboompics.com/ · Pexels Licence — source